Innovations in Needle-Free Drug Delivery Driven by Complex New Therapeutics

PressRelease by Kalorama Information

NEW YORK, NY -- (Marketwire) -- 08/19/11 -- Innovations in drug delivery will become a must as become increasingly sophisticated and the traditional delivery methods are no longer suitable, according to Kalorama Information. The healthcare market research publisher estimates that drug delivery methods -- which include patches, edible vaccines, pen injectors and more -- will likely see a significant increase in revenues, with annual growth averaging 15.1% from 2011 through 2016 to reach $6.2 billion, according to their new report on these systems.

technology has come into its own in the last 25 years. Initially seen as merely a medium for a drug, it is now viewed as a tool for modifying the pharmacologic properties of drugs, improving methods of delivery, and targeting drugs to specific locations. Progress in the fields of microencapulation, polymer technology and nanoparticles now allow scientists to prolong the effect of drugs with short half-lives, and companies are developing a new generation of sophisticated delivery systems.

Arizona Biodesign Institute in Tempe is in the vanguard of the movement toward edible vaccines. The institute has concluded three early-stage clinical trials using potatoes bearing vaccines against hepatitis B, E. coli and the Norwalk Virus. Similarly, researchers at Japan's National Institute of Agrobiological Sciences continue to develop an edible vaccine produced in genetically modified rice.

"The line between drug delivery and drug substance will become increasingly elusive in the near future, as researchers work to improve drug properties through drug design and molecular modeling," notes Bruce Carlson, Kalorama Information's publisher. "In the next decade, drug delivery technologies will be a focal point of competition and the success of specific drugs will be tied to innovative delivery techniques, which will enable the targeting that will exploit the clinical properties of a new generation of drugs."



Competition in the segment has already increased over the past 10 years, with top delivery technology companies such as Antares, Bioject, MediImmune and Zogenix taking a leading role. Bioject offers several proprietary delivery technologies, including Biojector 2000, Cool.click, Injex, Serojet, and Vitajet, which are used in a wide range of applications including insulin, vaccine, and hormone drug delivery. Zogenix offers the Intraject system, which is a pre-filled, disposable, needle-free injector for the delivery of a wide range of liquid drugs, therapeutic proteins, and vaccines.

More information about the report, , is available from Kalorama Information's website. This title includes a comprehensive market overview, descriptions of products on the market and in development, market estimates and forecasts, company profiles, trends in the industry and much more.

Kalorama Information supplies the latest in independent in diagnostics, biotech, , medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on and .





Please direct all media inquiries to:
Andrea Hiller



Keywords (optional):
needle, free-drug-delivery, injections, drug-delivery, vaccines, biologics, biotherapeutics,

further Information:
http://www.kaloramainformation.com

Kontakt-Informationen:
Firma: Kalorama Information
Stadt: NEW YORK, NY


Number of hits: 41

• Sales of Inhalers Driving Respiratory Device Market to $44 Billion
• Medical Device Market Looks to Innovations to Counter Cost Cuts: Kalorama
• Over-the-Counter Drug Sales Saw Little Boost From Recession: Kalorama
• Kalorama Report Describes Challenges for the Clinical Lab Business
• Competitive Bidding Will Dampen Sales Growth for Home Care Products
• EMR Opportunity Seen in Targeting Physicians With Web-Based Products
• Opportunity for Drug Makers in Products That Assist Anesthesia Process
• Kalorama Information: Tests That Personalize Results Show Sales Growth of up to 38%
• Weak Flu Market Shouldn't Affect Vaccine Sales: Kalorama
• Long Term Care Industry Grew 5.5% in Past Five Years: Kalorama
• more PressReleases by Kalorama Information

• Study Validating miRview mets2 Published in The Oncologist
• Rosetta Genomics to Raise $6.6 Million in Registered Direct Offering
• Insulet Corporation to Present at Upcoming Investor Conferences
• Mauna Kea Technologies Reports New Data Demonstrating Cellvizio(R)'s Potential as a Tool for the Characterization of Pancreatic Cysts
• Solos Endoscopy Releases ISO 13485 Certification and CE Mark Schedule With Work to Begin May 29
• LED Dental Announces Purchasing Agreement with Pacific Dental Services
• Moog Medical Devices Group Announces Voluntary Recall of Select Curlin Administration Sets Due to Possible Health Risk
• New Studies Confirm Value of Given Imaging's PillCam(R) SB in Managing Pediatric Patients With Inflammatory Bowel Disease
• New Data Show That Avantis Medical Systems' Third Eye(R) Retroscope(R) Device Significantly Increases Adenoma Detection Rate in Patients at Higher Risk for Colorectal Cancer
• New Studies Confirm Given Imaging's PillCam(R) COLON 2's Feasibility in an Outpatient Setting